Pharmaceuticals News and Research

RSS

Memorial Sloan Kettering Cancer Center, Quest Diagnostics partner for cancer tests

Memorial Sloan Kettering Cancer Center, the world's oldest and largest private cancer center, and Quest Diagnostics, the world's leading provider of diagnostic information services, today announced a joint collaboration that will utilize MSK's clinical and research insights into gene mutations associated with solid tumors.

From Quest Diagnostics 2 Jun 2014

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

Biothera will present research at the American Society of Clinical Oncology annual meeting linking a potential predictive serum biomarker to the clinical response to Imprime PGG immunotherapy in a recent phase 2 study in non-small cell lung cancer patients. The meeting begins today and runs through June 3 in Chicago.

31 May 2014

$ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM$

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

DelMar Pharmaceuticals, Inc. announced the presentation of interim clinical data from the company's ongoing clinical trial with VAL-083 in refractory glioblastoma multiforme (GBM) during the Central Nervous System Tumor Session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), which is being held at the McCormick Place Convention Center in Chicago.

31 May 2014

Eisai announces results from Phase III SELECT trial of lenvatinib evaluating PFS in patients with RR-DTC

Eisai Inc. announced today results from the Phase III SELECT trial of investigational agent lenvatinib evaluating progression-free survival (PFS) in patients with progressive radioiodine-refractory differentiated thyroid cancer (RR-DTC).

31 May 2014

OncLive announces 2014 Giants of Cancer Care

OncLive today announced the 2014 Giants of Cancer Care, 16 heroes in the oncology field whose careers have been dedicated to improving or prolonging the lives of those with cancer. The second annual Giants of Cancer Care class will be honored during a special reception tonight in Chicago.

31 May 2014

ASCO honors St. Jude researcher with 2014 Pediatric Oncology Award

The American Society of Clinical Oncology (ASCO) has named Leslie L. Robison, Ph.D., of St. Jude Children's Research Hospital the recipient of the 2014 Pediatric Oncology Award for his contributions to the field of childhood cancer survivorship research.

31 May 2014

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 – June 3, 2014.

31 May 2014

Pivotal Therapeutics reports reduced revenue in first quarter 2014

Pivotal Therapeutics Inc., ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the three months ended March 31, 2014.

31 May 2014

U.S. Court awards Teva favorable decision for generic Celebrex

Teva Pharmaceutical Industries Ltd. announced that the U.S. District Court for the Northern District of West Virginia denied a motion filed by Mylan and issued an opinion and order affirming a decision by the FDA under which Teva should receive sole 180-day "first-to-file" exclusivity for generic Celebrex® (celecoxib) 100, 200 and 400 mg capsules.

31 May 2014

Valeant, Pershing Square make revised proposal to acquire all outstanding shares of Allergan

Allergan, Inc. ("Allergan" or the "Company") today acknowledged that Valeant Pharmaceuticals International, Inc. ("Valeant") and Pershing Square Capital Management, L.P. ("Pershing Square") have made a second revised, unsolicited proposal to acquire all of the outstanding shares of the Company for a combination of 0.83 of Valeant common shares, $72.00 in cash per share of common stock of the Company, and a Contingent Value Right (CVR) related to DARPin® sales (the "Re-Revised Proposal").

31 May 2014

Deciphera initiates altiratinib MET/TIE2/VEGFR/TRK kinase inhibitor Phase 1 trial for solid tumors

Deciphera Pharmaceuticals, a clinical stage biotechnology company focused on improved kinase inhibitor treatments for cancer, today announced the initiation of a Phase 1 clinical trial of its MET/TIE2/VEGFR2/TRK inhibitor altiratinib (DCC-2701).

31 May 2014

Medtronic settles whistleblower case for $9.9 million

Suit accused the medical device maker of giving doctors gifts in return for using its products. Elsewhere, a federal judge denied dismissal of a lawsuit against Novartis alleging a kickback campaign to boost its drugs covered by Medicare and Medicaid.

31 May 2014

Inovio Pharmaceuticals’ reverse stock split to become effective on June 5, 2014

Inovio Pharmaceuticals, Inc. today announced that its previously announced 1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company's common stock on a post-reverse split basis shall commence on Friday, June 6, 2014.

30 May 2014

Newron Pharmaceuticals submits safinamide NDA to FDA

Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., an international pharmaceutical company strongly committed to the CNS therapeutic area with a long experience in respiratory disease therapies, woman care and primary care, announce that the New Drug Application (NDA) for safinamide was submitted today to the US Food and Drug Administration (FDA).

30 May 2014

Biomedical scientists explore mechanisms of novel treatments for HCV

As new treatments for hepatitis C virus (HCV) are approved, biomedical scientists are exploring their mechanisms and what they reveal about the virus.

29 May 2014

Mylan launches generic version of GlaxoSmithKline's Malarone Tablets

Mylan Inc. today announced that it has launched Atovaquone and Proguanil Hydrochloride Tablets, 62.5 mg/25 mg and 250 mg/100 mg, the generic version of GlaxoSmithKline's Malarone® Tablets.

29 May 2014

First Edition: May 29, 2014

Today's early morning highlights from the major news organizations, including articles on an inspector general's report on care at VA hospitals and growing pressure from some House Republicans to vote on an alternative to the Affordable Care Act.

29 May 2014

Synexus starts new state of art clinical trial centre in Bochum, Germany

On 28th May, 2014, Synexus officially opened a new state of the art clinical trial centre in Bochum, Germany.

From AES - Accelerated Enrollment Solutions 29 May 2014

Scientists report that coating stents with vitamin C reduces implants' risks

Every year, more than 1 million people in the U.S. who have suffered heart attacks or chest pain from blocked arteries have little mesh tubes called stents inserted into their blood vessels to prop them open.

29 May 2014

FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

Trimel Pharmaceuticals Corporation announced today that the United States Food and Drug Administration (FDA) has approved Natesto (testosterone), formerly CompleoTRT, the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

29 May 2014

Pharmaceuticals News and Research

Memorial Sloan Kettering Cancer Center, Quest Diagnostics partner for cancer tests

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

Eisai announces results from Phase III SELECT trial of lenvatinib evaluating PFS in patients with RR-DTC

OncLive announces 2014 Giants of Cancer Care

ASCO honors St. Jude researcher with 2014 Pediatric Oncology Award

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Pivotal Therapeutics reports reduced revenue in first quarter 2014

U.S. Court awards Teva favorable decision for generic Celebrex

Valeant, Pershing Square make revised proposal to acquire all outstanding shares of Allergan

Deciphera initiates altiratinib MET/TIE2/VEGFR/TRK kinase inhibitor Phase 1 trial for solid tumors

Medtronic settles whistleblower case for $9.9 million

Inovio Pharmaceuticals’ reverse stock split to become effective on June 5, 2014

Newron Pharmaceuticals submits safinamide NDA to FDA

Biomedical scientists explore mechanisms of novel treatments for HCV

Mylan launches generic version of GlaxoSmithKline's Malarone Tablets

First Edition: May 29, 2014

Synexus starts new state of art clinical trial centre in Bochum, Germany

Scientists report that coating stents with vitamin C reduces implants' risks

FDA approves Trimel’s Natesto nasal gel to treat adult males with low testosterone

Event guide: World ADC London eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence